Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TR 987

Drug Profile

TR 987

Alternative Names: Glucoprime; GLYC-101; MG-3601; TR987

Latest Information Update: 12 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glycotex; Novogen
  • Developer Glycotex; SerenaGroup; TR Therapeutics
  • Class Anti-inflammatories; Glucans
  • Mechanism of Action Dectin 1 stimulants; Macrophage stimulants; Toll-like receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Varicose ulcer; Wounds

Most Recent Events

  • 01 Jan 2017 Cosmetic Laser Dermatology completes a phase II trial for Wounds (In volunteers) in USA (NCT02681224)
  • 01 Sep 2015 Cosmetic Laser Dermatology initiates a phase IIb trial for Wounds (In volunteers) in USA (Topical) (NCT02681224)
  • 11 Aug 2015 No recent reports on development identified - Phase-II for Varicose ulcer in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top